Metagenomi, Inc. (MGX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Metagenomi, Inc. (MGX) trades at $1.29 with AI Score 18/100 (Grade F). Metagenomi, Inc. is a gene editing biotechnology company focused on developing novel therapeutics. Market cap: $48.56M, Sector: Healthcare.
Price live · AI analysis from May 7, 2026Analyst Coverage for MGX: MGX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MGX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MGX: 1/1 perspectives are bearish.
How is this calculated? →Metagenomi, Inc. (MGX) Healthcare & Pipeline Overview
Metagenomi, Inc. is a gene editing biotechnology company specializing in metagenomics-derived genome editing tools. Their focus is on developing therapeutics through strategic collaborations, including partnerships with ModernaTX, Affini-T Therapeutics, and Ionis Pharmaceuticals. The company aims to innovate in vivo human therapeutic applications within the competitive biotechnology landscape.
What Is the Investment Thesis for MGX?
Metagenomi, Inc. presents a notable research candidate within the gene editing sector. The company's proprietary metagenomics-derived genome editing toolbox offers a differentiated approach to developing therapeutics. Strategic collaborations with ModernaTX, Affini-T Therapeutics, and Ionis Pharmaceuticals validate the potential of Metagenomi's technology and provide avenues for future growth. Key value drivers include the advancement of in vivo human therapeutic applications through the ModernaTX partnership and the development of gene-edited T-cell receptor-based therapies with Affini-T Therapeutics. The collaboration with Ionis Pharmaceuticals further diversifies Metagenomi's pipeline and expands its reach in the pharmaceutical industry. However, the company's negative profit margin of -348.5% and small market capitalization of $48.56M highlight the risks associated with investing in an early-stage biotechnology company. Investors should closely monitor the progress of clinical trials and the company's ability to secure additional funding to sustain its operations.
Based on FMP financials and quantitative analysis
MGX Key Highlights
- Market Cap of $48.56M indicates a small-cap company with high growth potential but also higher risk.
- Profit Margin of -348.5% reflects significant investment in research and development, typical for early-stage biotech companies.
- Gross Margin of 0.3% suggests minimal revenue generation, highlighting reliance on partnerships and future product commercialization.
- Beta of 0.57 indicates lower volatility compared to the market, potentially due to strategic partnerships and long-term focus.
- Strategic collaborations with ModernaTX, Affini-T Therapeutics, and Ionis Pharmaceuticals validate the company's technology and provide multiple revenue streams.
Who Are MGX's Competitors?
MGX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | $59.20 | -2.58% | $5.71B | 44 |
| EDIT Editas Medicine, Inc. | $3.69 | -1.47% | $361.74M | — |
| NTLA Intellia Therapeutics, Inc. | $16.84 | -3.38% | $1.89B | — |
| SNDX Syndax Pharmaceuticals, Inc. | $24.63 | +5.96% | $2.18B | 79 |
| ANAB AnaptysBio, Inc. | $65.78 | -2.30% | $2.84B | 79 |
| XFOR X4 Pharmaceuticals, Inc. | $3.95 | +0.25% | $372.56M | 76 |
| CGEN Compugen Ltd. | $2.42 | +1.05% | $228.35M | 76 |
| AXSM Axsome Therapeutics, Inc. | $249.87 | +0.04% | $12.86B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MGX's Key Strengths?
- Proprietary metagenomics-derived genome editing toolbox.
- Strategic collaborations with leading pharmaceutical companies.
- Expertise in developing innovative gene editing therapies.
- Strong intellectual property portfolio.
What Are MGX's Weaknesses?
- Negative profit margin.
- Small market capitalization.
- Reliance on partnerships for revenue generation.
- Early-stage company with limited commercialized products.
What Could Drive MGX Stock Higher?
- Clinical trial results from gene-edited T-cell therapies developed with Affini-T Therapeutics.
- Progress updates on the ModernaTX collaboration for in vivo human therapeutic applications.
- Expansion of the company's proprietary gene editing toolbox.
- New strategic collaborations and partnerships to expand market reach.
What Are the Key Risks for MGX?
- Financial-distress signal — its Altman Z-Score of -2.48 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-51.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures and regulatory approval delays.
- Competition from established gene editing companies.
- Intellectual property disputes.
- Reliance on partnerships for revenue generation.
- Negative profit margin and need for additional funding.
What Are the Growth Opportunities for MGX?
- Expansion of ModernaTX Collaboration: The strategic collaboration with ModernaTX, Inc. offers significant growth potential by focusing on new genome editing systems for in vivo human therapeutic applications. This partnership could lead to the development of novel therapies for a wide range of diseases, potentially generating substantial revenue streams for Metagenomi. The global market for in vivo gene therapies is projected to reach $5 billion by 2028, providing a large addressable market for this collaboration.
- Advancement of Gene-Edited T-Cell Therapies with Affini-T Therapeutics: The development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene-edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer represents a key growth opportunity. The market for T-cell therapies is rapidly expanding, driven by the success of CAR-T cell therapies. The global T-cell therapy market is expected to reach $10 billion by 2027, offering a significant opportunity for Metagenomi and Affini-T Therapeutics.
- Commercialization of Investigational Medicines with Ionis Pharmaceuticals: The collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies provides another avenue for growth. Ionis Pharmaceuticals' expertise in RNA-targeted therapeutics complements Metagenomi's gene editing capabilities, potentially leading to the development of innovative treatments for genetic diseases. The market for RNA-targeted therapies is projected to reach $25 billion by 2028, providing a substantial market opportunity for this collaboration.
- Development of Proprietary Gene Editing Toolbox: Metagenomi's proprietary metagenomics-derived genome editing toolbox, including programmable nucleases, base editors, and RNA and DNA-mediated integration systems, offers a competitive advantage. The company can leverage this toolbox to develop its own pipeline of gene editing therapies, targeting a wide range of diseases. The global gene editing market is expected to grow significantly in the coming years, driven by advancements in gene editing technologies and increasing demand for personalized medicine.
- Strategic Acquisitions and Partnerships: Metagenomi can pursue strategic acquisitions and partnerships to expand its technology portfolio and market reach. Acquiring companies with complementary technologies or entering into partnerships with pharmaceutical companies can accelerate the development and commercialization of gene editing therapies. The biotechnology industry is characterized by frequent mergers and acquisitions, providing opportunities for Metagenomi to grow through strategic transactions.
What Opportunities Does MGX Have?
- Expansion of existing collaborations.
- Development of proprietary gene editing therapies.
- Strategic acquisitions and partnerships.
- Increasing demand for gene editing therapies.
What Threats Does MGX Face?
- Competition from established gene editing companies.
- Regulatory hurdles and approval delays.
- Clinical trial failures.
- Intellectual property disputes.
What Are MGX's Competitive Advantages?
- Proprietary metagenomics-derived genome editing toolbox.
- Strategic collaborations with leading pharmaceutical and biotechnology companies.
- Expertise in developing and applying gene editing technologies.
- Strong intellectual property portfolio protecting its gene editing tools and therapies.
What Does MGX Do?
Metagenomi, Inc., founded in 2016 and based in Emeryville, California, is a biotechnology company focused on revolutionizing gene editing. The company develops therapeutics for patients by utilizing its proprietary metagenomics-derived genome editing toolbox. This toolbox includes a range of advanced technologies such as programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. These tools enable precise and efficient gene editing, offering potential treatments for a variety of diseases. Metagenomi operates through strategic collaborations to expand its research and development capabilities. A key partnership is a strategic collaboration and license agreement with ModernaTX, Inc., focusing on the development of a new genome editing system for in vivo human therapeutic applications. This collaboration aims to create innovative therapies that can be delivered directly into the body. Additionally, Metagenomi has a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene-edited T-cell receptor-based therapeutic products for the treatment, prevention, or diagnosis of human cancer. Furthermore, the company collaborates with Ionis Pharmaceuticals, Inc. through a collaboration and license agreement to research, develop, and commercialize investigational medicines using genome editing technologies. Metagenomi's focus on cutting-edge gene editing technologies and strategic partnerships positions it as a key player in the rapidly evolving biotechnology industry. The company's innovative approach and collaborative spirit drive its mission to develop transformative therapies for patients in need.
What Products and Services Does MGX Offer?
- Develops therapeutics using metagenomics-derived genome editing tools.
- Creates programmable nucleases for precise gene editing.
- Engineers base editors to modify individual DNA bases.
- Designs RNA and DNA-mediated integration systems.
- Develops prime editing systems for targeted gene modifications.
- Utilizes clustered regularly interspaced short palindromic repeat-associated transposases (CRISPR-associated transposases).
- Collaborates with ModernaTX for in vivo human therapeutic applications.
- Partners with Affini-T Therapeutics for gene-edited T-cell therapies.
How Does MGX Make Money?
- Develops and licenses its gene editing technologies.
- Generates revenue through strategic collaborations and partnerships.
- Receives upfront payments, milestone payments, and royalties from partnered programs.
- Focuses on developing proprietary gene editing therapies for various diseases.
What Industry Does MGX Operate In?
Metagenomi operates in the rapidly evolving biotechnology industry, specifically within the gene editing sector. The market is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. The global gene editing market is projected to reach billions of dollars by 2030, driven by increasing demand for personalized medicine and innovative therapies. Metagenomi's strategic collaborations and proprietary technology position it to capitalize on this growth, but it faces competition from established players and emerging startups alike. The company's success will depend on its ability to navigate the complex regulatory landscape and demonstrate the efficacy and safety of its gene editing tools.
Who Are MGX's Key Customers?
- ModernaTX, Inc.
- Affini-T Therapeutics, Inc.
- Ionis Pharmaceuticals, Inc.
- Future pharmaceutical and biotechnology companies seeking gene editing solutions.
Company Profile
Metagenomi, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Emeryville, US. The company is led by CEO Jian Irish. MGX has traded publicly since 2006.
F-Score 2/9Financial Health
Metagenomi, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.48 places it in the distress zone, a signal of elevated financial risk.
ROE -51%Key Financial Metrics
Return on equity for Metagenomi, Inc. stands at -51.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -43.6%, showing how much profit it generates from its asset base. A current ratio of 6.43 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -189.7%, the inverse of the P/E and a quick read on earnings relative to price.
MGX Valuation & Market Position
With a $48.56M market cap, Metagenomi, Inc. sits in the micro-cap segment of the market. Relative to its peer group, MGX's quantitative score of 18/100 is below the peer average of 67/100.
FY2026 estForward Outlook
Wall Street analysts project Metagenomi, Inc. revenue of about $12.1M for fiscal 2026, with EPS near $-2.12. The estimate reflects 3 contributing analysts.
Net buyingInsider Activity
Over the past six months, Metagenomi, Inc. insiders filed 15 SEC Form 4 transactions — 5 sales and 10 purchases. On net that is roughly 640K shares acquired (about $740K) — insiders putting money in tends to read as conviction.
MGX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Metagenomi's growth potential, indicating that key stakeholders believe in the company's future.
- Community sentiment has turned positive, with discussions highlighting the innovative gene-editing technology that Metagenomi is developing.
- Recent partnerships and collaborations with biotech firms have bolstered the company's credibility and market position.
- Investors are optimistic about the potential applications of Metagenomi's technology in treating genetic disorders, driving interest in the stock.
Bear Case
- Some analysts express concerns regarding the competitive landscape in the biotech sector, which could pressure Metagenomi's market share.
- Negative sentiment emerged around the company's ability to secure funding for ongoing research and development, raising questions about sustainability.
- Recent regulatory hurdles in the biotech industry have led to skepticism about the timeline for product approvals, potentially delaying revenue.
- Community discussions reflect caution regarding the volatility of biotech stocks, which can be influenced by broader market trends and investor sentiment.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MGX Latest News
No recent news available for MGX.
MGX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MGX.
Price Targets
Wall Street price target analysis for MGX.
MGX MoonshotScore
What does this score mean?
The MoonshotScore rates MGX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jian Irish
CEO
Jian Irish is the Chief Executive Officer of Metagenomi, Inc. Her background includes extensive experience in the biotechnology industry, with a focus on strategic leadership and business development. She has a proven track record of driving innovation and building successful companies. Prior to joining Metagenomi, Jian held leadership positions at several biotechnology companies, where she played a key role in developing and commercializing novel therapies. She holds advanced degrees in molecular biology and business administration.
Track Record: Under Jian Irish's leadership, Metagenomi has secured strategic collaborations with ModernaTX, Affini-T Therapeutics, and Ionis Pharmaceuticals. She has overseen the expansion of the company's gene editing toolbox and the advancement of its pipeline of gene editing therapies. Jian has also been instrumental in raising capital to fund the company's research and development efforts. Her strategic vision and execution have positioned Metagenomi as a key player in the gene editing sector.
Common Questions About MGX (Healthcare)
What does Metagenomi, Inc. Common Stock do?
Metagenomi, Inc. is a gene editing biotechnology company that develops therapeutics using its proprietary metagenomics-derived genome editing toolbox. The company's toolbox includes a range of advanced technologies such as programmable nucleases, base editors, and RNA and DNA-mediated integration systems. Metagenomi collaborates with leading pharmaceutical and biotechnology companies to develop and commercialize innovative gene editing therapies for a variety of diseases. Their strategic partnerships with ModernaTX, Affini-T Therapeutics, and Ionis Pharmaceuticals are central to their business model, providing both funding and expertise to advance their therapeutic programs.
What do analysts say about MGX stock?
As of 2026-05-07, analyst coverage on Metagenomi, Inc. Common Stock (MGX) is still emerging due to its relatively recent entry into the public market. Initial assessments focus on the potential of its gene editing technology and the strength of its strategic collaborations. Key valuation metrics are closely tied to the progress of its clinical trials and the achievement of milestones in its partnerships. Growth considerations include the expansion of its technology platform and the successful commercialization of its gene editing therapies. Investors should monitor analyst reports for updates on the company's progress and evolving valuation.
What are the main risks for MGX?
The main risks for Metagenomi, Inc. include the inherent challenges of drug development, such as clinical trial failures and regulatory approval delays. The company also faces competition from established gene editing companies with greater resources and more advanced clinical programs. Intellectual property disputes and the need for additional funding are also significant risks. Furthermore, Metagenomi's reliance on partnerships for revenue generation exposes it to the risk of partner default or termination of agreements. Investors should carefully consider these risks before investing in MGX.
What are the key factors to evaluate for MGX?
Metagenomi, Inc. (MGX) holds an AI score of 18/100 (low). Not financial advice.
How frequently does MGX data refresh on this page?
MGX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MGX's recent stock price performance?
Metagenomi, Inc. (MGX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary metagenomics-derived genome editing toolbox. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MGX overvalued or undervalued right now?
Valuing Metagenomi, Inc. (MGX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying MGX?
Before investing in Metagenomi, Inc. (MGX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are based on the most recent available data.
- Analyst opinions are based on limited coverage and may not be representative of all viewpoints.